Ethic Inc. Cuts Stake in Repligen Corporation $RGEN

Ethic Inc. reduced its position in shares of Repligen Corporation (NASDAQ:RGEN) by 69.4% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,541 shares of the biotechnology company’s stock after selling 3,491 shares during the quarter. Ethic Inc.’s holdings in Repligen were worth $206,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. DekaBank Deutsche Girozentrale grew its holdings in shares of Repligen by 1.0% during the second quarter. DekaBank Deutsche Girozentrale now owns 7,830 shares of the biotechnology company’s stock valued at $961,000 after buying an additional 80 shares during the last quarter. Drive Wealth Management LLC boosted its stake in Repligen by 2.5% during the 2nd quarter. Drive Wealth Management LLC now owns 3,796 shares of the biotechnology company’s stock valued at $472,000 after purchasing an additional 93 shares during the last quarter. Hilltop National Bank increased its holdings in shares of Repligen by 8.0% in the 3rd quarter. Hilltop National Bank now owns 1,276 shares of the biotechnology company’s stock worth $171,000 after purchasing an additional 95 shares in the last quarter. ProShare Advisors LLC increased its holdings in shares of Repligen by 4.3% in the 2nd quarter. ProShare Advisors LLC now owns 2,316 shares of the biotechnology company’s stock worth $288,000 after purchasing an additional 96 shares in the last quarter. Finally, Louisiana State Employees Retirement System raised its stake in shares of Repligen by 0.7% in the second quarter. Louisiana State Employees Retirement System now owns 14,700 shares of the biotechnology company’s stock worth $1,828,000 after purchasing an additional 100 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Trading Down 1.9%

Repligen stock opened at $169.05 on Thursday. Repligen Corporation has a 12-month low of $102.96 and a 12-month high of $182.52. The firm has a market capitalization of $9.52 billion, a price-to-earnings ratio of 8,456.73, a P/E/G ratio of 3.12 and a beta of 1.12. The firm has a 50 day moving average of $160.08 and a 200 day moving average of $139.60. The company has a current ratio of 8.36, a quick ratio of 7.14 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share for the quarter, topping analysts’ consensus estimates of $0.42 by $0.04. The business had revenue of $188.81 million during the quarter, compared to analyst estimates of $181.23 million. Repligen had a net margin of 0.25% and a return on equity of 4.66%. The company’s revenue was up 21.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.43 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. As a group, research analysts predict that Repligen Corporation will post 1.72 earnings per share for the current year.

Insider Buying and Selling

In other Repligen news, COO James Bylund sold 2,191 shares of the stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $151.21, for a total value of $331,301.11. Following the completion of the sale, the chief operating officer owned 21,520 shares in the company, valued at approximately $3,254,039.20. This represents a 9.24% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Karen A. Dawes sold 275 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total value of $44,275.00. Following the sale, the director directly owned 91,821 shares in the company, valued at approximately $14,783,181. This represents a 0.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 49,657 shares of company stock valued at $7,721,077. Company insiders own 1.20% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Hsbc Global Res upgraded Repligen to a “strong-buy” rating in a report on Wednesday, October 1st. Wall Street Zen lowered shares of Repligen from a “buy” rating to a “hold” rating in a research note on Tuesday, November 4th. Canaccord Genuity Group increased their price objective on shares of Repligen from $150.00 to $165.00 and gave the company a “hold” rating in a research report on Wednesday, October 29th. HSBC started coverage on shares of Repligen in a research report on Wednesday, October 1st. They issued a “buy” rating and a $150.00 target price for the company. Finally, Evercore ISI increased their price target on Repligen from $155.00 to $175.00 and gave the company an “outperform” rating in a report on Tuesday, October 7th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $177.92.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.